# Drug Development, Clinical Trials and Regulation for NEET PG Pharmacology: Phases I–IV, NDCT Rules 2019, Ethics Committees, NLEM 2022 Source: https://tracknation.in/story/drug-development-clinical-trials-and-regulation-for-neet-pg-pharmacology-phases-i-iv-ndct-rules-2019-ethics-committees-nlem-2022 (TrackNation β€” free UPSC notes with PYQs) > NEET PG Pharmacology: the four phases of clinical trials and what each proves, efficacy versus effectiveness, what India's New Drugs and Clinical Trials Rules 2019 count as a new drug (including fixed-dose combinations), orphan drugs, Ethics Committee make-up, approval timelines, CTRI registration and serious adverse event reporting, and the National List of Essential Medicines 2022, with a diagram, hooks, MCQs and cards. ## Start Here 🎯 **Exam priority: Medium.** *Expect one question on trial phases (which phase gives most safety data, which is first-in-human) and sometimes one on Indian regulation: orphan drug, Ethics Committee composition, CTRI, or the essential medicines list.* CBME mapping: **PH 10** (applied pharmacology: drug development, regulation, essential medicines). ## The Four Phases *The four phases of clinical drug development. Objectives from the New Drugs and Clinical Trials Rules 2019; typical sizes from the MSD Manual. Drawn by TrackNation.* | **Phase** | **Also called** | **Main objective (NDCT Rules 2019)** | **Typical size (MSD Manual)** | | I | Human pharmacology | Safety and tolerability on first use in humans; maximum tolerated dose, PK, PD | Often 20–100, usually healthy volunteers | | II | Therapeutic exploratory | Effectiveness in patients with the condition; short-term side effects; dose for Phase III | Up to several hundred | | III | Therapeutic confirmatory | Confirms therapeutic benefit; basis for marketing approval | Hundreds to thousands; most safety data | | IV | Post-marketing | After approval, for the approved indication: interactions, safety, mortality and morbidity studies | Large, real-world | - Phase I is usually in healthy volunteers, but drugs with significant toxicity, such as cytotoxics, are studied in **patients**. - Phase II doses are usually below the highest Phase I doses; a key aim is choosing the dose for Phase III. - Phase III gives **most of the safety data** before approval; Phase IV picks up **uncommon or slowly developing** adverse effects missed by smaller, shorter trials. Older adults should be included in Phase III in meaningful numbers when the disease is one of ageing. ## Efficacy, Effectiveness and Outcomes - **Efficacy**: the ability to achieve the desired effect in a *controlled clinical setting* (a trial). - **Effectiveness**: the ability to achieve it in the *real world* after approval. A drug can lower blood pressure well in a trial yet be ineffective in practice if side effects make patients stop it. - **Surrogate outcomes** are intermediate measures (a lab value, an image, a physiological reading) used in place of the clinical outcome that matters. ## What the Law Calls a New Drug India's **New Drugs and Clinical Trials Rules, 2019** (under the Drugs and Cosmetics Act) govern trials and approval of new drugs. The regulator is the Central Licencing Authority. | **Counts as a "new drug" under the NDCT Rules** | **How long it stays "new"** | | A drug not used in India to any significant extent and not yet approved as safe and efficacious | 4 years from permission | | An approved drug with a new claim: indication, route, dose or dosage form | 4 years from permission | | A fixed-dose combination of separately approved drugs, combined for the first time or in a new ratio | 4 years from permission | | A modified or sustained release form, or a novel delivery system | Always deemed new | | A vaccine, rDNA product, monoclonal antibody, stem-cell or gene-therapy product, xenograft | Always deemed new | - **Investigational new drug**: a new chemical or biological entity not approved for marketing in any country. - **Orphan drug**: treats a condition affecting **not more than 5 lakh people in India**. - **Academic clinical trial**: an investigator- or institution-led trial of an already approved drug for a new indication, route, dose or dosage form, with results meant only for academic or research use. ## Ethics Committees and Trial Rules - **Composition**: at least **7 members**, including at least one **lay person**, one **woman**, one **legal expert** and one independent member (for example a social scientist or ethicist). At least **half** must be unaffiliated with the institution, and the **chairperson** must be unaffiliated. - **Registration**: every trial of a new drug must be registered with the **Clinical Trial Registry of India (CTRI)**, maintained by ICMR, before the first subject is enrolled. - **Timelines**: an application for a drug discovered in India, or researched and developed in India for manufacture and marketing here, is decided within **30 working days**; if the regulator does not reply, permission is deemed granted. Other trial applications are decided within **90 working days**. - **Serious adverse events**: the investigator reports within **24 hours**; the analysed report goes to the regulator, Ethics Committee chair and institution within **14 days**. A trial subject who is injured gets complete medical management and compensation. - Informed consent of **vulnerable subjects** in trials of a new chemical or molecular entity is **audio-video recorded**. Ethics Committees keep trial records for **5 years** after completion. No fee is charged for trials by government-funded or government-owned institutions. ## National List of Essential Medicines 2022 - **384 medicines** in **27 sections** (the last is COVID-19 management). Each medicine is tagged with the **level of healthcare** where it should be available: **P** (primary), **S** (secondary), **T** (tertiary). - **Added (34)**, including bedaquiline, nicotine replacement therapy and ormeloxifene (centchroman). - **Deleted (26)** from the 2015 list, including ranitidine, atenolol and sucralfate. ## Traps the Examiner Sets - First-in-human = Phase I; most pre-approval safety data = Phase III; rare and late ADRs = Phase IV. - Phase I is not always in healthy volunteers: cytotoxic drugs go straight to patients. - Efficacy is in a trial; effectiveness is in real life. - Orphan drug in India: a condition affecting ≀ 5 lakh people. - A new fixed-dose combination of old drugs is still a "new drug". - Ethics Committee: minimum 7; chair must be from outside the institution. - NLEM 2022 dropped ranitidine and atenolol. ## Memory Hooks & Shortcuts *Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.* - 🧠 **Safe β†’ Works β†’ Proves β†’ Watches** β€” Phase I safety, II works in patients, III proves benefit, IV watches after approval - 🧠 **Explore at Two, Confirm at Three** β€” Phase II therapeutic exploratory; Phase III therapeutic confirmatory - 🧠 **Seven on the panel, chair from outside** β€” Ethics Committee: at least 7; unaffiliated chairperson - 🧠 **Orphan = 5 lakh** β€” orphan drug: condition affecting ≀ 5 lakh people in India - 🧠 **Made in India, 30 days** β€” trial applications for drugs discovered in India: 30 working days - 🧠 **384 in 2022** β€” NLEM 2022 lists 384 medicines ## Rapid-Revision Cards - First in human; safety, tolerability, MTD, PK/PD; healthy volunteers (cytotoxics: patients). - Therapeutic exploratory; effectiveness in patients; dose for Phase III. - Therapeutic confirmatory; basis for approval; most safety data. - Post-marketing; rare and late ADRs. - I: 20–100 Β· II: up to several hundred Β· III: hundreds–thousands. - Desired effect in a controlled setting. - Desired effect in the real world after approval. - Intermediate measure used instead of the clinical outcome. - New Drugs and Clinical Trials Rules, 2019. - 4 years; vaccines, biologicals, modified-release always new. - First-time fixed ratio of approved drugs = new drug. - ≀ 5 lakh persons affected. - Not approved for marketing in any country. - Approved drug, new use; research only. - β‰₯ 7: lay person, woman, legal expert, independent member. - β‰₯ 50% unaffiliated; unaffiliated chair. - Register before first subject; maintained by ICMR. - Trial decision in 30 working days, else deemed approved. - Decision in 90 working days. - Investigator: 24 hours; analysed report: 14 days. - Vulnerable subjects in NCE/NME trials. - 384 medicines, 27 sections; P/S/T levels. - +34 (bedaquiline, NRT, centchroman); βˆ’26 (ranitidine, atenolol, sucralfate). ## Sources *Facts in this article were checked against these documents.* - New Drugs and Clinical Trials Rules, 2019 (G.S.R. 227(E)) β€” Ministry of Health and Family Welfare, Gazette of India (CDSCO copy), 2019 - MSD Manual Professional Edition: Evaluating Drug Efficacy and Safety β€” Merck & Co. (MSD Manuals), 2025 (link) - National List of Essential Medicines 2022 β€” Ministry of Health and Family Welfare, 2022 - Competency Based Undergraduate Curriculum, Pharmacology (PH 10) β€” National Medical Commission, 2024 ## Test Yourself: Practice Questions Twenty-four questions in NEET PG style, including clinical vignettes. ## Practice Questions (NEET PG pattern) *Original questions written in the style of the exam: +4 for a correct answer, βˆ’1 for a wrong one. Every answer was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.* **Q1.** The first administration of an investigational new drug to humans, to estimate safety and tolerability, is - (a) Phase I - (b) Phase III - (c) Phase IV - (d) Phase II **Answer: (a)** β€” Phase I estimates safety and tolerability with the initial administration of an investigational new drug into humans. **Q2.** Phase I trials of a cytotoxic anticancer drug are usually done in - (a) animals only - (b) healthy volunteers - (c) children only - (d) patients **Answer: (d)** β€” Drugs with significant potential toxicity, such as cytotoxics, are usually studied in patients. **Q3.** Phase II trials are also called - (a) therapeutic confirmatory trials - (b) therapeutic exploratory trials - (c) post-marketing surveillance - (d) human pharmacology trials **Answer: (b)** β€” Phase II = therapeutic exploratory; Phase III = therapeutic confirmatory. **Q4.** An important goal of Phase II is to - (a) detect very rare adverse effects - (b) find the maximum tolerated dose in healthy volunteers - (c) obtain marketing approval - (d) determine the dose and regimen for Phase III **Answer: (d)** β€” Phase II evaluates effectiveness in patients and sets the dose and regimen for Phase III. **Q5.** Which phase provides most of the safety data before a drug is approved? - (a) Phase III - (b) Phase IV - (c) Phase I - (d) Phase II **Answer: (a)** β€” Phase III studies hundreds to thousands of patients and provides most of the safety data. **Q6.** Rare or slowly developing adverse effects are most likely to be detected in - (a) Phase III - (b) Phase I - (c) Phase IV - (d) Phase II **Answer: (c)** β€” Phase IV (post-marketing) can detect uncommon or slowly developing adverse effects missed by smaller, shorter trials. **Q7.** Under the NDCT Rules 2019, 'effectiveness' means a drug's ability to achieve the desired effect - (a) in healthy volunteers - (b) in a controlled clinical setting - (c) in animal studies - (d) in a real-world clinical situation after approval **Answer: (d)** β€” Efficacy = controlled setting; effectiveness = real world after approval. **Q8.** In India, an orphan drug treats a condition affecting not more than - (a) 10 lakh persons - (b) 50,000 persons - (c) 5 lakh persons - (d) 1 lakh persons **Answer: (c)** β€” NDCT Rules 2019: a condition affecting not more than five lakh persons in India. **Q9.** Which of these is always deemed a 'new drug' under the NDCT Rules 2019? - (a) A drug used widely in India for decades - (b) A generic of a drug approved ten years ago - (c) A monoclonal antibody - (d) An over-the-counter antacid **Answer: (c)** β€” Vaccines, rDNA products, monoclonal antibodies, stem-cell and gene-therapy products (and modified-release forms) are always deemed new drugs. **Q10.** Two separately approved drugs are combined for the first time in a fixed ratio. Under the NDCT Rules this product - (a) is an investigational new drug in every country - (b) is an orphan drug - (c) is a new drug - (d) needs no approval **Answer: (c)** β€” A first-time fixed-dose combination of separately approved drugs is a 'new drug'. **Q11.** Most drugs approved as 'new drugs' stay in that category for - (a) 1 year - (b) until the patent expires - (c) 4 years from permission - (d) 10 years **Answer: (c)** β€” Drugs other than modified-release forms and biologicals such as vaccines remain new drugs for four years. **Q12.** The minimum number of members of an Ethics Committee for clinical trials under the NDCT Rules is - (a) 7 - (b) 3 - (c) 11 - (d) 5 **Answer: (a)** β€” At least seven members, including a lay person, a woman, a legal expert and an independent member. **Q13.** The chairperson of a clinical-trial Ethics Committee must be - (a) a member not affiliated with the institution - (b) the principal investigator - (c) the head of the institution - (d) a government official **Answer: (a)** β€” At least half the members, and the chairperson, must be unaffiliated with the institution. **Q14.** Before enrolling the first subject, a clinical trial in India must be registered with - (a) the WHO - (b) the Indian Pharmacopoeia Commission - (c) the state drug controller only - (d) the Clinical Trial Registry of India (ICMR) **Answer: (d)** β€” CTRI, maintained by ICMR, before the first subject is enrolled. **Q15.** An application to trial a drug discovered in India must be decided within - (a) 30 working days, failing which permission is deemed granted - (b) 6 months - (c) 90 working days - (d) 7 days **Answer: (a)** β€” Drugs discovered or developed in India: 30 working days; deemed approval if no communication. Others: 90 working days. **Q16.** An investigator must report a serious adverse event in a trial within - (a) 24 hours of its occurrence - (b) 7 days - (c) 30 days - (d) the end of the trial **Answer: (a)** β€” Within twenty-four hours to the regulator, sponsor and Ethics Committee; the analysed report within 14 days. **Q17.** Audio-video recording of informed consent is required for - (a) every trial participant - (b) bioequivalence studies only - (c) Phase IV studies only - (d) vulnerable subjects in trials of a new chemical or molecular entity **Answer: (d)** β€” NDCT Rules: audio-video recording of the consent process for vulnerable subjects in NCE/NME trials. **Q18.** A trial of an already approved drug for a new indication, run by a university with results only for research, is - (a) a bioequivalence study - (b) a Phase I trial - (c) a global clinical trial - (d) an academic clinical trial **Answer: (d)** β€” Academic clinical trial: approved drug, new indication/route/dose/form, investigator-initiated, academic use only. **Q19.** How many medicines does the National List of Essential Medicines 2022 contain? - (a) 348 - (b) 384 - (c) 376 - (d) 410 **Answer: (b)** β€” NLEM 2022 lists 384 medicines in 27 sections. **Q20.** In NLEM 2022, the letters P, S and T against a medicine indicate - (a) its price band - (b) the level of healthcare where it should be available - (c) its schedule under drug law - (d) its pregnancy safety category **Answer: (b)** β€” Primary, secondary and tertiary level of healthcare. **Q21.** Which drug was deleted from the national essential medicines list in 2022? - (a) Bedaquiline - (b) Ranitidine - (c) Ormeloxifene - (d) Nicotine replacement therapy **Answer: (b)** β€” Ranitidine, atenolol and sucralfate were among 26 deletions; bedaquiline, NRT and ormeloxifene among 34 additions. **Q22.** A blood-pressure drug works well in trials but patients stop it because of side effects. It has - (a) high efficacy but low effectiveness - (b) high potency - (c) low efficacy and high effectiveness - (d) a narrow therapeutic index **Answer: (a)** β€” Efficacy is shown under trial conditions; effectiveness depends on real-world use. **Q23.** A company develops a drug for a rare metabolic disease that affects about 3 lakh people in India. Under the NDCT Rules this is - (a) an investigational product only after marketing - (b) an academic clinical trial - (c) not a new drug - (d) an orphan drug **Answer: (d)** β€” Orphan drug: a condition affecting not more than five lakh persons in India. **Q24.** A new injectable is approved after Phase III. Two years later a rare liver injury is recognised that trials of a few thousand patients missed. This shows the role of - (a) bioequivalence studies - (b) Phase IV post-marketing studies - (c) Phase I - (d) Phase II **Answer: (b)** β€” Phase IV can detect uncommon or slowly developing adverse effects missed in smaller, shorter trials. ### Active Recall From memory: describe the four phases of clinical trials with their aims and typical sizes; distinguish efficacy from effectiveness; state what counts as a new drug and an orphan drug in India; list the Ethics Committee requirements, the CTRI rule and the SAE timelines; and give the key facts of NLEM 2022.